Fluid overload at start of continuous renal replacement therapy is associated with poorer clinical condition and outcome: a prospective observational study on the combined use of bioimpedance vector analysis and serum N-terminal pro-B-type natriuretic peptide measurement

Haiyan Chen, Buyun Wu, Dehua Gong, Zhihong Liu, Haiyan Chen, Buyun Wu, Dehua Gong, Zhihong Liu

Abstract

Introduction: It is unclear whether the fluid status, as determined by bioimpedance vector analysis (BIVA) combined with serum N-terminal pro-B-type natriuretic peptides (NT-pro-BNP) measurement, is associated with treatment outcome among patients receiving continuous renal replacement therapy (CRRT). Our objective was to answer this question.

Methods: Patients who were in the intensive care units of a university teaching hospital and who required CRRT were screened for enrollment. For the enrolled patients, BIVA and serum NT-pro BNP measurement were performed just before the start of CRRT and 3 days afterward. According to the BIVA and NT-pro BNP measurement results, the patients were divided into four groups according to fluid status type: type 1, both normal; type 2, normal BIVA results and abnormal NT-pro BNP levels; type 3, abnormal BIVA results and normal NT-pro BNP levels; and type 4, both abnormal. The associations between fluid status and outcome were analyzed.

Results: Eighty-nine patients were enrolled, 58 were males, and the mean age was 49.0 ± 17.2 years. The mean score of Acute Physiology and Chronic Health Evaluation II (APACHE II) was 18.8 ± 8.6. The fluid status before CRRT start was as follows: type 1, 21.3% (19 out of 89); type 2, 16.9% (15 out of 89); type 3, 11.2% (10 out of 89); and type 4, 50.6% (45 out of 89). There were significant differences between fluid status types before starting CRRT on baseline values for APACHE II scores, serum creatinine, hemoglobin, platelet count, urine volume, and incidences of oliguria and acute kidney injury (P <0.05). There were significant differences between patients with different fluid status before CRRT start on hospital mortality--type 1, 26.3% (5 out of 19); type 2, 33.3% (5 out of 15); type 3, 40% (4 out of 10); and type 4, 64.4% (29 out of 45) (P = 0.019)--as well as renal function recovery rates: type 1, 57.1% (4 out of 7); type 2, 67.7% (6 out of 9); type 3, 50% (3 out of 6); and type 4, 23.7% (9 out of 38) (P = 0.051).

Conclusions: Fluid status abnormalities were common among patients receiving CRRT. Different types of fluid status distinguished by BIVA combined with serum NT-pro BNP measurements corresponded to different clinical conditions and treatment outcomes, which implies a value of this method for evaluation of fluid status among patients receiving CRRT.

Figures

Figure 1
Figure 1
Kaplan-Meier survival curves for patients with different fluid status at start of continuous renal replacement therapy. The type of fluid status was determined by combination of bioimpedance vector analysis and serum N-terminal pro-B-type natriuretic peptide (NT-pro-BNP).

References

    1. Investigators RRTS, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Crit Care Med. 2012;40:1753–60.
    1. Lombel RM, Kommareddi M, Mottes T, Selewski DT, Han YY, Gipson DS, et al. Implications of different fluid overload definitions in pediatric stem cell transplant patients requiring continuous renal replacement therapy. Intensive Care Med. 2012;38:663–9. doi: 10.1007/s00134-012-2503-6.
    1. Onofriescu M, Hogas S, Voroneanu L, Apetrii M, Nistor I, Kanbay M, et al. Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial. Am J Kidney Dis. 2014;64:111–8. doi: 10.1053/j.ajkd.2014.01.420.
    1. Ronco C, Kaushik M, Valle R, Aspromonte N. Peacock WFt: Diagnosis and management of fluid overload in heart failure and cardio-renal syndrome: the ‘5B’ approach. Semin Nephrol. 2012;32:129–41. doi: 10.1016/j.semnephrol.2011.11.016.
    1. Arjamaa O. Physiology of natriuretic peptides: The volume overload hypothesis revisited. World J Cardiol. 2014;6:4–7. doi: 10.4330/wjc.v6.i1.4.
    1. Valle R, Aspromonte N. Use of brain natriuretic Peptide and bioimpedance to guide therapy in heart failure patients. Contrib Nephrol. 2010;164:209–16. doi: 10.1159/000313732.
    1. Piccoli A, Rossi B, Pillon L, Bucciante G. A new method for monitoring body fluid variation by bioimpedance analysis: the RXc graph. Kidney Int. 1994;46:534–9. doi: 10.1038/ki.1994.305.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1–138.
    1. Jeong EG, Nam HS, Lee SM, An WS, Kim SE, Son YK. Role of B-type natriuretic peptide as a marker of mortality in acute kidney injury patients treated with continuous renal replacement therapy. Ren Fail. 2013;35:1216–22. doi: 10.3109/0886022X.2013.823870.
    1. Berri RN, Sahai SK, Durand JB, Lin HY, Folloder J, Rozner MA, et al. Serum brain naturietic peptide measurements reflect fluid balance after pancreatectomy. J Am Coll Surg. 2012;214:778–87. doi: 10.1016/j.jamcollsurg.2012.01.046.
    1. Davies SJ, Davenport A. The role of bioimpedance and biomarkers in helping to aid clinical decision-making of volume assessments in dialysis patients. Kidney Int. 2014;86:489–96. doi: 10.1038/ki.2014.207.
    1. Lara TM, Hajjar LA, de Almeida JP, Fukushima JT, Barbas CS, Rodrigues AR, et al. High levels of B-type natriuretic peptide predict weaning failure from mechanical ventilation in adult patients after cardiac surgery. Clinics (Sao Paulo). 2013;68:33–8. doi: 10.6061/clinics/2013(01)OA05.
    1. Davenport A. Changes in N-terminal pro-brain natriuretic peptide correlate with fluid volume changes assessed by bioimpedance in peritoneal dialysis patients. Am J Nephrol. 2012;36:371–6. doi: 10.1159/000343286.
    1. Tapolyai M, Faludi M, Reti V, Lengvarszky Z, Szarvas T, Fulop T, et al. Volume estimation in dialysis patients: the concordance of brain-type natriuretic peptide measurements and bioimpedance values. Hemodial Int. 2013;17:406–12. doi: 10.1111/hdi.12023.
    1. Agarwal R. B-type natriuretic peptide is not a volume marker among patients on hemodialysis. Nephrol Dial Transplant. 2013;28:3082–9. doi: 10.1093/ndt/gft054.
    1. Muller L, Louart G, Teboul JL, Mahamat A, Polge A, Bertinchant JP, et al. Could B-type Natriuretic Peptide (BNP) plasma concentration be useful to predict fluid responsiveness [corrected] in critically ill patients with acute circulatory failure? Ann Fr Anesth Reanim. 2009;28:531–6. doi: 10.1016/j.annfar.2009.04.003.
    1. Levitt JE, Vinayak AG, Gehlbach BK, Pohlman A, Van Cleve W, Hall JB, et al. Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study. Crit Care. 2008;12:R3. doi: 10.1186/cc6764.
    1. Maeder MT, Rickenbacher P, Rickli H, Abbuhl H, Gutmann M, Erne P, et al. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) Eur J Heart Fail. 2013;15:1148–56. doi: 10.1093/eurjhf/hft076.
    1. de Leeuw K, Nieuwenhuis MK, Niemeijer AS, Eshuis H, Beerthuizen GI, Janssen WM. Increased B-type natriuretic peptide and decreased proteinuria might reflect decreased capillary leakage and is associated with a better outcome in patients with severe burns. Crit Care. 2011;15:R161. doi: 10.1186/cc10297.
    1. Papanikolaou J, Makris D, Mpaka M, Palli E, Zygoulis P, Zakynthinos E. New insights into the mechanisms involved in B-type natriuretic peptide elevation and its prognostic value in septic patients. Crit Care. 2014;18:R94. doi: 10.1186/cc13864.
    1. Pimenta J, Paulo C, Mascarenhas J, Gomes A, Azevedo A, Rocha-Goncalves F, et al. BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. Int J Cardiol. 2010;145:209–14. doi: 10.1016/j.ijcard.2009.08.001.
    1. Parrinello G, Torres D, Paterna S, Di Pasquale P, Licata G. Wet BNP, fluid and hemodynamic status at discharge in acute heart failure. Int J Cardiol. 2010;145:335–6. doi: 10.1016/j.ijcard.2009.11.059.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa